AMPK activation reduces vascular permeability and airway inflammation by regulating HIF/VEGFA pathway in a murine model of toluene diisocyanate-induced asthma

Inflammation Research

Volumn 61, Issue 10, 2012, Pages 1069-1083

  Park, Seoung Ju ^a,b   Lee, Kyung Sun ^a,b   Kim, So Ri ^a   Chae, Han Jung ^b   Yoo, Wan Hee ^a,b   Kim, Dong Im ^a,b   Jeon, Myoung Shin ^a,b   Lee, Yong Chul ^a,b  

^a Chonbuk National University Medical School and Hospital   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

AMP activated protein kinase; Asthma; Hypoxia inducible factor; Reactive oxygen species; Vascular endothelial growth factor A

Indexed keywords

2 METHOXYESTRADIOL; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; CBO P 11; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TOLUENE DIISOCYANATE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; ENZYME ACTIVATION; FEMALE; MOUSE; NONHUMAN; OCCUPATIONAL ASTHMA; PATHOGENESIS; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ASTHMA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; PNEUMONIA; REACTIVE OXYGEN SPECIES; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TOLUENE 2,4-DIISOCYANATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867400434     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0499-6     Document Type: Article

References (57)

1. Gautrin D, Newman-Taylor AJ, Nordman H, Malo JL. Controversies in epidemiology of occupational asthma. Eur Respir J. 2003;22:551-9.
2. Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol. 2009;123:531-42.
3. Carling D. AMP-activated protein kinase: balancing the scales. Biochimie. 2005;87:87-91.
4. Nath N, Giri S, Prasad R, Salem ML, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol. 2005;175:566-74.
5. Peairs A, Radjavi A, Davis S, Li L, Ahmed A, Giri S, et al. Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. Clin Exp Immunol. 2009;156:542-51.
6. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond). 2009;116:607-20.
7. Kim AS, Miller EJ, Young LH. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol (Oxf). 2009;196:37-53.
8. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229:558-65.
9. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. BioEssays. 2001;23:1112-9.
10. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y, et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295:L497-504.
11. Sag D, Carling D, Stout RD, Suttles J. Adenosine 50- monophosphateactivated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181:8633-41.
12. Kim TB, Kim SY, Moon KA, Park CS, Jang MK, Yun ES, et al. Five-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates poly (I:C)-induced airway inflammation in a murine model of asthma. Clin Exp Allergy. 2007;37:1709-19.
13. Alba G, El Bekay R, Alvarez-Maqueda M, Chacón P, Vega A, Monteseirýń J, et al. Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett. 2004;573:219-25.
14. Park SJ, Lee YC. Antioxidants as novel agents for asthma. Mini Rev Med Chem. 2006;6:235-40.
15. Barrett N, Austen KF. Airway inflammation in asthma: Th2 cell immunity and beyond. Immunity. 2009;31:425-37.
16. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332:133-8.
17. Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007;176:858-64.
18. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63:601-10.
19. Toldi G, Molvarec A, Stenczer B, Müller V, Eszes N, Bohács A, et al. Peripheral T (h) 1/T (h) 2/T (h) 17/regulatory T-cell balance in asthmatic pregnancy. I. Int Immunol. 2011;23:669-77.
20. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010;40:1232-40.
21. Xue K, Zhou Y, Xiong S, Xiong W, Tang T. Analysis of CD4+ CD25+ regulatory T cells and Foxp3 mRNA in the peripheral blood of patients with asthma. J Huazhong Univ Sci Technolog Med Sci. 2007;27:31-3.
22. Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol. 2010;151:297-307.
23. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223:114-31.
24. John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1 alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med. 1998;157:256-62.
25. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet. 1998;352:113.
26. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergenspecific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199:1567-75.
27. Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy. 2009;39:1815-21.
28. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Immunol. 2002;168:3595-600.
29. Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med. 2004;169:1125-30.
30. Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J. 2001;15:2480-8.
31. Wen FQ, Liu X, Manda W, Terasaki Y, Kobayashi T, Abe S, et al. TH2 cytokine-enhanced and TGF beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol. 2003;111:1307-18.
32. Kazi AS, Lotfi S, Goncharova EA, Tliba O, Amrani Y, Krymskaya VP, et al. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am J Physiol Lung Cell Mol Physiol. 2004;286:L539-45.
33. Faffe DS, Flynt L, Mellema M, Moore PE, Silverman ES, Subramaniam V, et al. Oncostatin M causes eotaxin-1 release from airway smooth muscle: synergy with IL-4 and IL-13. J Allergy Clin Immunol. 2005;115:514-20.
34. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004;10:1095-103.
35. Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells. 2010;29:435-42.
36. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA. 1997;94:4273-8.
37. Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003;17:271-3.
38. Lee SY, Kwon S, Kim KH, Moon HS, Song JS, Park SH, et al. Expression of vascular endothelial growth factor and hypoxiainducible factor in the airway of asthmatic patients. Ann Allergy Asthma Immunol. 2006;97:794-9.
39. Tournoy KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy. 2000;30:79-85.
40. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med. 1997;186:449-54.
41. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, et al. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factorkappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006;118:120-7.
42. Hur GY, Kim SH, Park SM, Ye YM, Kim CW, Jang AS, et al. Tissue transglutaminase can be involved in airway inflammation of toluene diisocyanate-induced occupational asthma. J Clin Immunol. 2009;29:786-94.
43. Robinson DS. Regulatory T cells and asthma. Clin Exp Allergy. 2009;39:1314-23.
44. Treins C, Murdaca J, Van Obberghen E, Giorgetti-Peraldi S. AMPK activation inhibits the expression of HIF-1alpha induced by insulin and IGF-1. Biochem Biophys Res Commun. 2006;342:1197-202.
45. Henderson WR Jr, Chi EY, Teo JL, Nguyen C, Kahn M. A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol. 2002;169:5294-9.
46. Mahajan SG, Mali RG, Mehta AA. Effect of Moringa oleifera Lam. seed extract on toluene diisocyanate-induced immune-mediated inflammatory responses in rats. J Immunotoxicol. 2007;4:85-96.
47. Kim SH, Park HJ, Lee CM, Choi IW, Moon DO, Roh HJ, et al. Epigallocatechin-3-gallate protects toluene diisocyanate-induced airway inflammation in a murine model of asthma. FEBS Lett. 2006;580:1883-90.
48. Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY. AMPactivated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitateinduced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008;106:394-403.
49. Biswas S, Gupta MK, Chattopadhyay D, Mukhopadhyay CK. Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol. 2007;292:H758-66.
50. Lee KS, Kim SR, Park HS, Park SJ, Min KH, Lee KY, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-kappaB and hypoxia-inducible factor-1alpha. Exp Mol Med. 2007;39:756-68.
51. Irwin DC, McCord JM, Nozik-Grayck E, Beckly G, Foreman B, Sullivan T, et al. A potential role for reactive oxygen species and the HIF-1alpha-VEGF pathway in hypoxia-induced pulmonary vascular leak. Free Radic Biol Med. 2009;47:55-61.
52. Lloyd CM, Hawrylowicz CM. Regulatory T cells in asthma. Immunity. 2009;31:438-49.
53. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol. 2009;182:8005-14.
54. Kim SR, Lee KS, Park SJ, Min KH, Lee MH, Lee KA, et al. A novel dithiol amide CB3 attenuates allergic airway disease through negative regulation of p38 MAPK. Am J Respir Crit Care Med. 2011;183:1015-24.
55. Karol MH. Animal models of occupational asthma. Eur Respir J. 1994;7:555-68.
56. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. Allergy Asthma Immunol Res. 2009;1:10-8.
57. Persson CG, Erjefalt JS, Korsgren M, Sundler F. The mouse trap. Trends Pharmacol Sci. 1997;18:465-7.